Mesenchymal Stem Cell Therapy in Feline IBD: Can It Match Standard Prednisolone Treatment?

Managing feline inflammatory bowel disease (IBD) remains challenging in clinical practice. Long-term daily medication, variable treatment response, and the potential adverse effects associated with immunosuppressive therapy often make disease management frustrating for both veterinarians and cat owners. While prednisolone continues to be the standard therapeutic approach, interest in regenerative medicine has expanded rapidly, particularly regarding mesenchymal stem cell (MSC) therapy¹. 

Current evidence suggests that feline adipose-derived mesenchymal stem cells (fMSCs) may offer clinically meaningful improvement in cats with histologically confirmed IBD while potentially reducing dependence on chronic immunosuppressive medication. Comparisons with standard prednisolone therapy have shown encouraging clinical outcomes, supporting growing interest in MSC-based treatment approaches for feline gastrointestinal disease. 

Why MSC Therapy Is Being Investigated 

MSCs have attracted attention because of their immunomodulatory and anti-inflammatory properties. These cells appear capable of migrating to sites of inflammation and influencing immune responses through interactions with T cells, B cells, and other inflammatory mediators^1,2. This mechanism is particularly relevant in IBD, where dysregulated intestinal immune activity plays a central role. 

Human medicine has already explored MSC use in inflammatory bowel disorders such as Crohn’s Disease and Ulcerative Colitis. Multiple studies have reported clinical improvement following intravenous administration of MSCs, with some patients successfully tapering corticosteroid therapy after treatment. Importantly, intravenous MSC infusion has also demonstrated a favorable safety profile in human clinical trials^1,3. 

Encouraging findings have similarly emerged in veterinary medicine. Previous canine studies reported significant improvement in clinical indices, albumin levels, and intestinal histopathology following MSC therapy^1,4,5. These findings helped support further exploration of MSC treatment in cats with confirmed IBD. 

Treatment Approach and Clinical Monitoring¹ 

Cats receiving fMSC therapy were administered two intravenous infusions of freshly cultured, allogeneic adipose-derived fMSCs two weeks apart, while the comparison group received conventional prednisolone therapy. 

Clinical response was monitored over a six-month period using the Feline Chronic Enteropathy Activity Index (FCEAI) alongside fecal scoring assessments. 

Clinical Outcomes and Practical Relevance¹ 

Clinical response between the two treatment approaches was broadly comparable, with five cats in each group successfully completing the six-month monitoring period. One treatment failure occurred in each group. 

An important observation was the statistically significant improvement in FCEAI scores over time within the fMSC-treated group. Fecal scores also trended toward improvement, although statistical significance was not reached (P=0.098). Notably, these improvements occurred without documented adverse effects related to stem cell administration. 

From a practical clinical perspective, the potential reduction in long-term corticosteroid dependence may represent one of the most valuable aspects of MSC therapy. Chronic prednisolone use in cats can create management challenges, particularly in patients with concurrent disease risks or in households where daily medication compliance is difficult. 

Safety and Long-Term Observations¹ 

One of the most reassuring findings associated with repeated allogeneic fMSC infusions was the absence of adverse reactions following either administration. This supports previous evidence suggesting that MSCs possess low major histocompatibility complex class II expression and may evade clinically significant immune recognition. 

Although extended long-term follow-up was not the primary focus, anecdotal outcomes remained noteworthy. Three to four years after treatment, four of the five cats from the fMSC group that completed the monitoring period were reportedly alive with normal appetite, activity, and stool quality. Vomiting had either resolved completely or become infrequent in cats where it was initially a major complaint. 

Conclusion 

Available evidence suggests that allogeneic adipose-derived fMSC therapy may represent a clinically valuable alternative to standard prednisolone treatment in feline IBD. The combination of favorable safety findings, meaningful clinical improvement, and the possibility of reducing reliance on chronic immunosuppressive therapy positions MSC treatment as an important area of advancement in feline gastroenterology.  

Reference 

1. Webb TL, Webb CB. Comparing adipose-derived mesenchymal stem cells with prednisolone for the treatment of feline inflammatory bowel disease. Journal of feline medicine and surgery. 2022 Aug;24(8):e244-50. https://journals.sagepub.com/doi/pdf/10.1177/1098612X221104053 

2. Cao Y, Ding Z, Han C, Shi H, Cui L, Lin R. Efficacy of mesenchymal stromal cells for fistula treatment of Crohn’s disease: a systematic review and meta-analysis. Digestive diseases and sciences. 2017 Apr;62(4):851-60. https://doi.org/10.1007/s10620-017-4453-x 

3. Huang F, Thokerunga E, He F, Zhu X, Wang Z, Tu J. Research progress of the application of mesenchymal stem cells in chronic inflammatory systemic diseases. Stem Cell Research & Therapy. 2022 Jan 8;13(1):1. https://link.springer.com/content/pdf/10.1186/s13287-021-02613-1.pdf 

4. Webb TL, Webb CB. Stem cell therapy in cats with chronic enteropathy: a proof-of-concept study. Journal of feline medicine and surgery. 2015 Oct;17(10):901-8. https://journals.sagepub.com/doi/pdf/10.1177/1098612X14561105 
5. Cristóbal JI, Duque FJ, Usón-Casaús JM, Ruiz P, Nieto EL, Pérez-Merino EM. Effects of allogeneic mesenchymal stem cell transplantation in dogs with inflammatory bowel disease treated with and without corticosteroids. Animals. 2021 Jul 10;11(7):2061. https://www.mdpi.com/2076-2615/11/7/2061